Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NEK2 | P51955 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4541666 | 0.91 | FASN (0.55) | FASNSMN1; SMN2ALDH1A1MEN1MAPK1 | |
| SCHEMBL4538519 | 0.86 | FASN (0.51) | FASNSMN1; SMN2ALDH1A1MEN1MAPK1 | |
| SCHEMBL4538120 | 0.86 | FASN (0.50) | FASNSMN1; SMN2ALDH1A1MEN1MAPK1 | |
| SCHEMBL4538507 | 0.86 | FASN (0.50) | FASNSMN1; SMN2ALDH1A1MEN1MAPK1 | |
| SCHEMBL4543321 | 0.85 | SIGMAR1 (0.48) | FASNSMN1; SMN2ALDH1A1MEN1MAPK1 | |
| SCHEMBL4538083 | 0.82 | FASN (0.51) | FASNSMN1; SMN2ALDH1A1MEN1MAPK1 | |
| SCHEMBL4536900 | 0.82 | FASN (0.46) | FASNSMN1; SMN2ALDH1A1MEN1MAPK1 | |
| SCHEMBL4533607 | 0.82 | FASN (0.46) | FASNSMN1; SMN2ALDH1A1MEN1MAPK1 | |
| SCHEMBL4541664 | 0.82 | FASN (0.46) | FASNSMN1; SMN2ALDH1A1MEN1MAPK1 | |
| SCHEMBL4541813 | 0.80 | FASN (0.44) | FASNSMN1; SMN2ALDH1A1MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2637660-A1 | FATTY ACID SYNTHASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-09-12 | — | — | US | disclosed |
| WO-2012064642-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | FASN 1/4885SMN1; SMN2 4521/4885ALDH1A1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.